Correspondence | Published:

Chronic myeloproliferative neoplasms

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Ethics declarations

Compliance with ethical standards

Conflict of interest

FHH has served as an advisory board member for Novartis Inc., AH received research support from Novartis, BMS, Incyte and Pfizer. The other authors declare that they have no conflict of interest.

References

  1. 1.

    Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.

  2. 2.

    Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96:1653–65.

  3. 3.

    Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. J Cancer Res Clin Oncol. 2016;142:2041–9.

  4. 4.

    Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016;97:192–200.

  5. 5.

    Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.

  6. 6.

    Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, et al. Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia 2018. (In press)

  7. 7.

    Kremyanskaya M, Najfeld V, Mascarenhas J, Hoffman R. The polycythemias. In: Hoffman R, editor. Hematology - Basic Principles and Practice. 6th ed: Philadelphia: Elsevier Saunders; 2013. p. 998–1033.

  8. 8.

    Labbe RF, Dewanji A. Iron assessment tests: transferrin receptor vis-a-vis zinc protoporphyrin. Clin Biochem. 2004;37:165–74.

  9. 9.

    Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem. 1994;40:768–73.

  10. 10.

    Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.

Download references

Author information

Conflict of interest

FHH has served as an advisory board member for Novartis Inc., AH received research support from Novartis, BMS, Incyte and Pfizer. The other authors declare that they have no conflict of interest.

Correspondence to Andreas Hochhaus.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading